Using Chimeric Antigen Receptor (CAR) technology, Thunder Biotech genetically modifies T-cells and other immune cells to target unique cancer biomarkers. CAR T-cells have shown significant success in the treatment of hematological malignancies, such as lymphoma and leukemia, and show promise for malignant tumors as well.
Within the tumor microenvironment, there is a substantial presence of Tumor-Associated Macrophages (TAMs) that aid in tumor growth and help protect the tumor from immune destruction. Thunder Biotech has developed a genetically immune cell – MOTO-CAR™ to target unique biomarkers on the surface of malignant tumor cells and initiate immune activation leading to tumor cell destruction.
ENVISON A CANCER FREE FUTURE
Watch our proprietary MOTO-CAR™ recognize and destroy a lung tissue cancer cell.
OUR COMPANION DIAGNOSTIC/
Thymidine Kinase 1 (TK1) is an enzyme involved in the salvage pathway of DNA synthesis. Research studies have shown that TK1 is up-regulated in malignant tumor cells and is expressed on the surface of the cells. Thunder Biotech has successfully developed a standard ELISA assay that can accurately detect the TK1 levels in serum. Unlike commercially available TK1 assays, the sensitivity of our proprietary assay can precisely detect TK1 levels in serum at various stages of tumor progression making it a novel companion diagnostic/prognostic for our immunotherapy. An advantage of this non-invasive assay is that it only requires a simple blood draw to complete.
OUR ANTIBODY STAIN
Thunder Biotech developed a proprietary antibody for an immunohistochemical (IHC) stain of the TK1 protein. The IHC stain is highly sensitive and selectively images TK1 in malignant tissue sections. The resulting image has a clarity that is superior to regular staining methods. As a laboratory developed test, translation from benchtop to clinical application is underway.
“Cancer may have started the fight, but I will finish it.”